Archive for the ‘Conference Coverage with Social Media’ Category

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]

Data collection from Twitter Analytics Pages for above Twitter Account: Aviva Lev-Ari, PhD, RN


An engagement rate between 0.09% and 0.33% is considered to be high, where an influencer would expect 0.9 – 3.3 reactions for every 1000 followers onTwitter. Finally, an engagement rate between 0.33% and 1% is considered to be very high, with expected reactions to be between 3.3 – 10 for every 1000 Twitter followers.

What is a Good Engagement Rate on Twitter? – Scrunch

How to calculate engagement rate on Twitter?

The Tweet Engagement Rate Formula.
The Tweet Engagement Rate takes into account the Replies and Retweets of the Tweet to the total number of Followers to date. Then it´s multiplied by 100 as well to provide you with the percentage of your Fan base that´s interacting with your Tweet.

Formulas Revealed: The Facebook and Twitter Engagement Rate …

6 engagement rate calculation methods

These are the most common formulas you’ll need to calculate engagement rates on social media.

Total engagements typically represents a tally of likes, favourites, reactions, comments, shares, views, retweets, and sometimes include clicks, depending on which platform you’re using.

1. Engagement rate by reach (ERR)

This formula is the most common way to calculate engagement with content.

ERR measures the percentage of people who chose to interact with your content after seeing it.

Use the first formula for a single post, and the second one to calculate the average rate across multiple posts.

  • ERR = total engagements per post / reach per post * 100

To determine the average, add up the all the ERRs from the posts you want to average, and divide by number of posts:

  • Average ERR = Total ERR / Total posts

In other words: Post 1 (3.4%) + Post 2 (3.5%) / 2 = 3.45%

Pros: Reach can be a more accurate measurement than follower count, since not all your followers will see all your content. And non-followers may have been exposed to your posts through shares, hashtags, and other means.

Cons: Reach can fluctuate for a variety of reasons, making it a different variable to control. A very low reach can lead to a disproportionately high engagement rate, and vice versa, so be sure to keep this in mind.

2. Engagement rate by posts (ER post)

Technically, this formula measures engagements by followers on a specific post. In other words, it’s similar to ERR, except instead of reach it tells you the rate at which followers engage with your content.

Most social media influencers calculate their average engagement rate this way.

  • ER post = Total engagements on a post / Total followers *100

To calculate the average, add up all the ER posts you want to average, and divide by number of posts:

  • Average ER by post = Total ER by post / Total posts

Example: Post 1 (4.0%) + Post 2 (3.0%) / 2 = 3.5%

Pros: While ERR is a better way to gauge interactions based on how many people have seen your post, this formula replaces reach with followers, which is generally a more stable metric.

In other words, if your reach fluctuates often, use this method for a more accurate measure of post-by-post engagement.

Cons: As mentioned, while this may be a more unwavering way to track engagements on posts, it doesn’t necessarily provide the full picture since it doesn’t account for viral reach. And, as your follower count goes up, your rate of engagement could drop off a little.

Make sure to view this stat alongside follower growth analytics.

Bonus: Get a free social media report template to easily and effectively present your social media performance to key stakeholders.

Get the free template now!

3. Engagement rate by impressions (ER impressions)

Another base audience metric you could choose to measure engagements by is impressions. While reach measures how many people see your content, impressions tracks how often that content appears on a screen.

  • ER impressions = Total engagements on a post / Total impressions *100
  • Average ER impressions = Total ER impressions / Total posts

Pros: This formula can be useful if you’re running paid content and need to evaluate effectiveness based on impressions.

Cons: An engagement rate calculated with impressions as the base is bound to be lower than ERR and ER post equations. Like reach, impression figures can also be inconsistent. It may be a good idea to use this method in conjunction with reach.

Read more about the difference between reach and impressions.

4. Daily engagement rate (Daily ER)

While engagement rate by reach measures engagement against maximum exposure, it’s still good to have a sense of how often your followers are engaging with your account on a daily basis.

  • Daily ER = Total engagements in a day / Total followers *100
  • Average Daily ER = Total engagements for X days / (X days *followers) *100

Pros: This formula is a good way to gauge how often your followers interact with your account on a daily basis, rather than how they interact with a specific post. As a result, it takes engagements on new and old posts into equation.

This formula can also be tailored for specific use cases. For instance, if your brand only wants to measure daily comments, you can adjust “total engagements” accordingly.

Cons: There’s a fair amount of room for error with this method. For instance, the formula doesn’t account for the fact that the same follower may engage 10 times in a day, versus 10 followers engaging once.

Daily engagements can also vary for a number of reasons, including how many posts you share. For that reason it may be worthwhile to plot daily engagement versus number of posts.

5. Engagement rate by views (ER views)

If video is a primary vertical for your brand, you’ll likely want to know how many people choose to engage with your videos after watching them.

  • ER view = Total engagements on video post / Total video views *100
  • Average ER view = Total ER view / Total posts

Pros: If one of your video’s objectives is to generate engagement, this can be a good way to track it.

Cons: View tallies often include repeat views from a single user (non-unique views). While that viewer may watch the video multiple times, they may not necessarily engage multiple times.

6. Factored Engagement Rate

In rare cases some marketers use a “factored engagement rate.” As the name suggests, factored engagement rates add more or less weight to certain factors in the equation.

For example, a marketer may wish to place a higher value on comments versus likes, weighting each comment as two versus one. The subsequent equation would look something like this:

  • Comment-weighted ER = (Total comments x 2) + all other engagements / Reach per post *100

Obviously, this technique inflates the resulting engagement rate and can be misleading, especially since the use of factored engagement rates is not widespread. For this reason, Hootsuite does not recommend its use.


How To Measure An Influencer’s Engagement Rate (A Scientific …



July 2019

Impressions, Engagement Rate, Link Clicks, Retweets, Likes, Replies



Average Impressions per day by Month



Engagement Rate


Last day of the month



Link Clicks

& Last day of the month

& average link clicks per day


Average Retweets

& Last day of the month

& average Retweets per day




& Last day of the month

& average Likes per day


Average Replies

& Last day of the month

& average Replies per day

January 31

N = 809

2.4% / 2.2% 33 / 3 / 1 80 / 4 / 3 129 / 5 / 4

2 /1 /0

February 28

N = 825

2.1% / 11.7% 22 / 0 / 1 24 / 3 / 1 41 / 1 / 1

1 / 0 / 0

March 31

N = 759

2.5% / 0.5% 18 / 1/ 1 37 / 1/ 1 63 / 1 / 2 1 / 0 / 0

April 30

N = 2.1K

1.0% / 1.8% 21 / 1/ 1 130 / 3 / 4 201 / 3 / 7

0 / 0/ 0

May 31

N = 2.3K

1.3% / 1.2% 51 / 3 / 2 117 / 2 / 4 142 / 2 / 5

3 / 0 / 0

June 30

N = 1.9K

1.2% / 0.1% 33 / 0 / 1 124 / 1 / 4 161 / 0 / 5

1 / 0 / 0

July 31

N = 824

0.9% / 1.1% 54 / 4/ 2 42 / 6 / 1 40 / 3 / 1

3 / 0 / 0


N =


N =


N =


N =

Tweets, Impressions, Profile Visits, Mentions, New Followers


Tweets Impressions Profile visits Mentions New Followers


25.1K 21


1 23.1K 62


March 155 23.5K 533 153



257 64.2K 690 235 14


281 70.4K 691 238




58.4K 581 170



83 25.5K 321 62








Top Tweet earned 2,280 impressions

as and are in unidirectional symbiosis Food affect Microbiome in turn it affects of individuals over theirs
 5  4

Top Follower followed by 289K people

@tveitdal FOLLOWS YOU

Tweeting Climate Change news. Climate lecturer: science, policy, solutions. Director Klima 2020, former UN Director. For contact use

Top mention earned 21 engagements

eProceeding 2019 Koch Institute Symposium – 18th Annual Cancer Research Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PMET MIT Kresge Auditorium, Cambridge, MA via
 1  1



Tweet impressions


Profile visits




New followers


Top Tweet earned 3,800 impressions

create application for robots, we picked pruned by hand in high school as Summer job.
 6  5

Top Follower followed by 202K people

@Alex_Verbeek FOLLOWS YOU

Public Speaker | Moderator | Diplomat | Photographer | Yale World Fellow | Climate Change | Wildlife | Environment | Art | Energy-Water-Food | Sustainability 🌱

Top mention earned 36 engagements

 6  10

Top media Tweet earned 1,319 impressions

Dr. Maus ⁩ monitoring data from clinical trial is very important development of new targets multiple drugs multiple mechanism multiple specificities more modification to one cell contamination results
 3  3



Tweet impressions


Profile visits




New followers


Top Tweet earned 2,758 impressions

The premise of applied to 30 babies in 1st week of life new to intervention to cause desirable # molecular changes by search immunology search
 7  12

Top media Tweet earned 1,652 impressions

Amazing Disruptive Dozen Technologies ⁩ ⁦ Third Annette Kim streamlining Diagnosis Second Thomas McCoy prediction of Suicide risk FIRST Alexandra Golby Neurosurgery Imaging AI based system real time dynamic data intraop
 1  1



Tweet impressions


Profile visits




New followers


Top Follower followed by 450K people

@CMichaelGibson FOLLOWS YOU

Non-Profit Founder/Leader | ❤️ Doc | Artist | Scientist | Educator | Med News Anchor | RT ≠ endorse | Disclaimer here:

Top mention earned 8 engagements

impact of , how to maintain Boston as Biotech HUB? with ⁦⁩ attract great talent ⁦⁦⁩ culture is asset on the balance sheet PARKING
 1  2

Top media Tweet earned 440 impressions




Tweet impressions


Profile visits




New followers


Top Tweet earned 795 impressions

Top Follower followed by 252K people

@ArtistsandMusic FOLLOWS YOU

Music Lovers Network . ♫♫ Connecting  talented  with , A&Rs and Fans.   

Top mention earned 6 engagements

Top media Tweet earned 55 impressions

My week on Twitter 🎉: 34 Mentions, 10.6K Mention Reach, 18 Likes, 7 Retweets, 6.7K Retweet Reach. See yours with



Tweet impressions


Profile visits


New followers


Top Follower followed by 450K people

@CMichaelGibson FOLLOWS YOU

Non-Profit Founder/Leader | ❤️ Doc | Artist | Scientist | Educator | Med News Anchor | RT ≠ endorse | Disclaimer here:


Tweet impressions


New followers


Read Full Post »

MinneBOS 2019, Field Guide to Data Science & Emerging Tech in the Boston Community

August 22, 2019, 8AM to 5PM at Boston University Questrom School of Business, 595 Commonwealth Avenue, Boston, MA



MinneBOS – Boston’s Field Guide to Data Science & Emerging Tech


Leaders in Pharmaceutical Business Intelligence (LPBI) Group


REAL TIME Press Coverage for 


 Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal,

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine,





Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series




Thursday, August 22 • 9:30am – 10:15am
Histopathological images are the gold standard tool for cancer diagnosis, whose interpretation requires manual inspection by expert pathologists. This process is time-consuming for the patients and subject to human error. Recent advances in deep learning models, particularly convolutional neural networks, combined with big databases of patient histopathology images will pave the path for cancer researchers to create more accurate guiding tools for pathologists. In this talk, I will review the latest advances of big data in healthcare analytics and focus on deep learning applications in cancer research. Targeted at a general audience, I will provide a high-level overview of technical concepts in deep learning image analysis, and describe a typical cloud-based workflow for tackling such big data problems. I will conclude my talk by sharing some of our most recent results based on a wide range of cancer types.


avatar for Mohammad Soltanieh-ha, PhD

Mohammad Soltanieh-ha, PhD

Clinical Assistant Professor, Boston University – Questrom
Mohammad is a faculty at Boston University, Questrom School of Business, where he teaches data analytics and big data to master’s students. Mohammad’s current research area involves deep learning and its applications in cancer research.



Thursday, August 22 • 10:30am – 11:00am

Deep learning image recognition and classification models for fashion items

Large scale image recognition and classification is an interesting and challenging problem. This case study uses fashion-MNIST dataset that involves 60000 training images and 10000 testing images. Several popular deep learning models are explored in this study to arrive at a suitable model with high accuracy. Although convolutional neural networks have emerged as a gold-standard for image recognition and classification problems due to speed and accuracy advantages, arriving at an optimal model and making several choices at the time of specifying model architecture, is still a challenging task. This case study provides the best practices and interesting insights.


avatar for Bharatendra Rai

Bharatendra Rai

Professor, UMass Dartmouth
Bharatendra Rai, Ph.D. is Professor of Business Analytics in the Charlton College of Business at UMass Dartmouth. His research interests include machine learning & deep learning applications.
  • Train data: 60,000
  • Test data: 10,000
  • Dataset available from Google MNIST Fashion Data – items in DB: data already labelled
  • Label and Description
  • Architecture: Input >> Conv >> Conv >> Pooling >> Dropout << Dense <<Flatten << Dropout >> Output
  • CNN vs Fully connected: 320 parameters: 3x3x1x32 + [32 BIAS TERM] = 320 vs
  • fully connected network parameters is 16 million
  • Train the model: 15 iterations – Training and Validation
  • Actual vs Predicted: 94% was classified correctly = Accuracy: 94% 5974 vs 4700 (78%)
  • Confusion Matrix – Test 720 correctly classified for item 6  – Probability va Actual Vs Predicted
  • Image generation: Noise . gnerator Network > fake Image vs Real image – GAN Loss va Discriminator Loss
  • CNN network help reduce # of parameter
  • Droppot layers can help reduce overfitting
  • validation split of x%chooses last x% of train data
  • Generation of new data is challenging



Thursday, August 22 • 11:15am – 12:00pm

Rapid Data Science

Most companies today require fast, traceable, and actionable answers to their data questions. This talk will present the structure of the data science process along with cutting edge developments in computing and data science technology (DST) with direct applications to real world problems (with a lot of pictures!). Everything from modeling to team building will be discussed, with clear business applications.


avatar for Erez Kaminski

Erez Kaminski

Leaders Global Operations Fellow, MIT
Erez has spent his career helping companies solve problems using data science. He is currently a graduate student in computer science and business at MIT. Previously, he worked in data science at Amgen Inc. and as a technologist at Wolfram Research.



Thursday, August 22 • 1:00pm – 1:45pm

Health and Healthcare Data Visualization – See how you’re doing

Health and healthcare organizations are swimming in data but few have the skills to show and see the story in their data using the best practices of data visualization. This presentation raises awareness about the research that inform these best practice and stories from the front of groups who are embracing them and re-imagining how they display their data and information. These groups include the NYC Dept of Health & Mental Hygiene, The Centers for Medicare and Medicaid (CMS), and leading medical centers and providers across the country.


avatar for Katherine Rowell

Katherine Rowell

Co-Founder & Principal, Health Data Viz
Katherine Rowell is a health, healthcare, and data visualization expert. She is Co-founder and Principal of HealthDataViz, a Boston firm that specializes in helping healthcare organizations organize, design and present visual displays of data to inform their decisions and stimulate… Read More →
  • dashboard for Hospital CEOs



Thursday, August 22 • 2:00pm – 2:45pm

AI in Healthcare

Benefits, challenges and impact of AI and Cybersecurity on medicine.


avatar for Vinit Nijhawan

Vinit Nijhawan

Lecturer, Boston University
Vinit Nijhawan is an Entrepreneur, Academic, and Board Member with a track record of success, including 4 startups in 20 years.
  • US: Spends the most on Health Care (HC) death per 100K people is the highest
  • Eric Topol – Diagnosis is not done correctly, AI will help with diagnosis
  • Diagnosis — AI will have the most impact; VIRAL infections are diagnosed as bacterial infections and get antibiotics for treatment
  • Image Classification my ML – decline below to human misclassification
  • Training Data sets – Big data
  • Algorithms getting better
  • Data Capture getting better – HC as well
  • Investment in HC is the greatest
  • SECURITY related to Implentable Medical Devices = security attacks – hacking and sending signal to implentable devices




Thursday, August 22 • 3:00pm – 3:30pm

Patient centric AI: Saving lives with ML driven hospital interventions

This presentation will cover the use of machine learning for maximizing the impact of a hospital readmissions intervention program. With machine learning, clinical care teams can identify and focus their intervention efforts on patients with the highest risk of readmission. The talk will go over the goals, logistics, and considerations for defining, implementing, and measuring our ML driven intervention program. While covering some technical details, this presentation will focus on the business implementation of advanced technology for helping people live healthier lives.


avatar for Miguel Martinez

Miguel Martinez

Data Scientist, Optum
Miguel Martinez is a Data Scientist at Optum Enterprise Analytics. Relied on as a tech lead in advancing AI healthcare initiatives, he is passionate about identifying and developing data science solutions for the benefit of organizations and people.




Thursday, August 22 • 3:45pm – 4:15pm

Using Ontologies to Power AI Systems

There’s a great deal of confusion about the role of a knowledge architecture in artificial intelligence projects. Some people don’t believe that any reference data is necessary. But in reality reference data is required- even if there is no metadata or architecture definitions outside defined externally for an AI algorithm, someone has made the decisions about architecture and classification within the program. However, this will not work for every organization because there are terms, workflows, product attributes, and organizing principles that are unique to the organization and that need to be defined for AI tools to work most effectively.


avatar for Seth Earley

Seth Earley

CEO, Earley Information Science
Seth Earley is a published author and public speaker about artificial intelligence and information architecture. He wrote “There’s no AI without IA” which has become an industry catchphrase used by a number of people including Ginny Rometty, the CEO of IBM.
  • Ontology, taxonomies, thesauri – conceptual relationships
  • Object-Oriented Programming and Information Architecture using AI is Old wine in new bottles


Thursday, August 22


 Senior Leadership Panel: Future Directions of Analytics

This panel includes senior leaders from across industry, academia & government to discuss challenges they are tackling, needs they anticipate and goals they will achieve


avatar for Bonnie Holub, PhD

Bonnie Holub, PhD

Industry & Business Data Science, Teradata
Bonnie has a PhD in Artificial Intelligence and specializes in correlating disparate sets of Big Data for actionable results.

Read Full Post »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group


is pleased to announce its sponsorship and invite you to attend

The New England Venture Summit presented by youngStartup Ventures.

Special discount offered   

Use discount code LPBI-VIP and receive 10% off the “early bird” rates.


Call for Top Innovators to present to leading Investors (details below).


New England Venture Summit

December 3rd & 4th 2019 | Hilton | Boston, Dedham

Where Innovation Meets Capital




Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Lifesciences/Healthcare Track at the prestigious New England Venture Summit being held on December 3rd & 4th 2019 at the Hilton in Boston, Dedham.


Whether you’re a Lifescience/Healthcare startup seeking capital and exposure, or a Biotech investor seeking new deals, The New England Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.


A highly productive venture conference, the Lifesciences/Healthcare track at The New England Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 UPDATED on 8/27/2019


VCs & Angel Investors confirmed to speak and judge includes:

Mark Austin, Managing Director, Viridian Capital | Greg Bohlen, Managing Director, Union Grove Venture Partners | Ciara Burnham, Partner, QED Investors | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Jesse Draper, Founding Partner, Halogen Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Emilia Gonzalez, Principal, Joyance Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Jay Karandikar, Venture Partner, New Crop Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Darwin Ling, Founding General Partner, Good AI Capital | Sarah Millar, Associate, City Light Capital | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Tayo Sanders, Associate, Anzu Partners | Reese Schroeder, Managing Director, Tyson Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Alex Steiner, Investment Analyst, Anthemis Group | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Raymond Wang, Investor, Two Sigma Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…


Lineup of over 120 VCs & Angels that spoke and judged at NEVS18 includes:

Karine Agajanian, Analyst, Anzu Ventures | Sanjay Aggarwal, Venture Partner, F-Prime Capital Partners | Magdi Amin, Investment Partner, Omidyar Network | Peter Arkell, Investor, Norwest Venture Partners | Mark Austin, Partner, Bright Capital | Salman Azhar, Managing Director, Duke Angel Network | Ibraheem Badejo, Sr. Director, Johnson & Johnson Innovation | Sunny Bai, Associate, CRCM Ventures | Janet Bannister, Partner, Real Ventures | Peter Bastien, Partner, Next47 | Alex Beletsky, Investor, Sidecar Angels | Woody Benson, Venture Partner, Launch Capital | Joshua Berg, Investment Manager, GM Ventures | Raghav Bhargava, Associate, NEA | Victor Bian, Associate, Intellectual Ventures | Laura Bock, Investor, QED Investors | Nabil Borhanu, Managing Partner, Graphene Ventures | Will Borthwick, Senior Associate, Bold Capital Partners | Lee Bouyea, Managing Director, FreshTracks Capital | Eric Breese, Managing Director, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Dan Burstein, Managing Partner, Millennium Technology Value Partners | Jason Cahill, Founder & Managing Director, McCune Capital | Neil Callahan, Co-Founder and Managing Director, Pilot Growth Equity | Efayomi Carr, Associate, Quona Capital | Sara Chamberlain, Managing Director, Energy Foundry | Raymond Chang, Managing Director, NXT Ventures | Christopher Chu, Managing Director, Samsung Catalyst Fund | Meghan Cross Breeden, Managing Partner, Red Bear Angels | David Cruikshank, Partner, ARCH Venture Partners | Sophia Dardashti, Associate, WorldQuant Ventures | Ekaterina Dorozhkina, Managing Partner, Starta Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kathryn Meng Elmes, Investment Associate, Massachusetts Clean Energy Center | Alison Ernst, Senior Manager of Investments, Massachusetts Clean Energy Center | Teresa Esser, Managing Director, Silicon Pastures | Michael Fanfant, Investor, Runa Capital | David Feldman, Analyst, Indicator Ventures | Mark G. Fields, Partner, Alsop Louie Partners | Shawn Flynn, Investment Director, Bay Angels | Prashant Fonseka, Principal, Tuesday Capital | Haley Fradkin, Investment Associate, Plum Alley | Lisa Frusztajer, Investor, Portfolia Enterprise Fund | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Matt Gatto, Partner, Insight Venture Partners | Joy Ghosh, Investor, Bain Capital Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Jamil Goheer, Managing Partner & Cofounder, CoVenture | Ben Gorman, Associate, F-Prime Capital Partners | Edward Greer, Corporate Technology Scout, Dow Ventures | Jacob E. Grose, Investment Manager, BASF Venture Capital | Zain Gulamali, Investor, Amazon Alexa Fund | Marina Hadjipateras, Co-Founder & General Partner, Trail Mix Ventures | Hunter Hartwell, Principal, Forte Ventures | Laurence Hayward, Founding Partner, Independence Equity | Nathaniel Henshaw, Managing Director, CEI Ventures | Michael Hoeksema, Associate, Battery Ventures | Lindsay Hyde, Venture Partner, Moderne Ventures | Oren Isacoff, Principal, Longitude Capital | Nicolas Jacques-Bouchard, Principal, Panache Ventures | Jamie James, Managing Partner, GreenSoil Building Innovation Fund | Noel Jee, Investor, Illumina Ventures | Lacey Johnson, Principal, Green D Ventures | Ajay Kamat, Managing Director, Pear Ventures | Alex Kaufman, Investment Associate, JetBlue Technology Ventures | Shane Kelly, Head of Investments, CrowdSmart | Patrick Kenealy, Managing Director, Ridge Ventures | Jack Kerrigan, Managing Director, Razor’s Edge Ventures | Jonathan Kerstein, Associate, Red Sea Ventures | Nyla Koncurat, Managing Partner, Karlani Capital | Daniel Kwak, Investor, Point72 Ventures | Vivek Ladsariya, Partner, SineWave Ventures | Donna Lecky, Managing Director, Health Venture Capital | Linus Liang, Senior Associate, Signia Venture Partners | Bion Ludwig, Partner, Savano Capital Partners | Kyle Lui, Principal, DCM Ventures | Tamim Abdul Majid, Principal, OCA Ventures | Nurzhas Makishev, Managing Partner, NKM Capital | Eller Mallchok, Managing Director, Jumpstart Foundry | Coppelia Marincovic, Investment Manager, Solvay Ventures | Olga Maslikhova, Managing Partner, Phystech Ventures | Tom Mastrobuoni, Chief Financial Officer, Tyson Ventures | Hiroki Matsuda, Investor, Sozo Ventures | Derek Mazur, Senior Associate, Sante Ventures | David Miller, Co-Founder and Managing Director, Clean Energy Ventures | Julia Moore, Partner, Breakout Ventures | Kirsten Morbeck, Managing Director, SpringRock Ventures | Amit Mulgaonkar, Investor, Mithril Capital Management | Sheila Narayan, Managing Director, Golden Seeds | David Nault, General Partner, Luge Capital | Sara M. Nayeem, Partner, NEA | Brian Panoff, Senior Principal, Shell Ventures | Sumay Parikh, Principal, Quake Capital | Daniel Povitsky, Vice President, Sinai Ventures | Vinny Pujji, Investor, Insight Venture Partners | Venu Raghavan, Vice President, Wasson Enterprise | Gopal Rajaraman, Investment Principal , Motorola Solutions Venture Capital | Wanda Reindorf, Managing Director, Clean Energy Ventures | Brendan Rempel, Associate, OpenView Venture Partners | Martin Ringlein, Venture Partner, NextGen Venture Partners | Praveen Sahay, Managing Director, WAVE Equity Partners | Louis Schick, Founding Partner, NewWorld Capital Group | Chris Seitz, Associate, Excel Venture Management | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Alex Shtarkman, Associate, Revolution | John Simon, Managing Director, Sigma Prime Ventures | Sidarth Singh, Investor, Stripes Group | Emily Snyder, Associate, Borealis Ventures | Vivek Soni, Managing Director, TiE-Boston Angels | Siri Srinivas, Associate, Draper Associates | Luisa Sucre, Associate, Revolution | Lyndsey Toeppen, Vice President, Sandbox Insurtech Ventures | Tibor Toth, Managing Director, Massachusetts Clean Energy Center | Laurel Touby, Partner, Supernode Ventures | Chisom Uche, Associate, SixThirty | Alexander Urban, Principal, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Maria Velissaris, Investor, Pipeline Angels | Anthony Walsh, Principal, BioInnovation Capital | John Wei, Sr. Investment Manager, SABIC Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Christopher J. Whalen, Managing Director, New Technology Ventures | Thomas Whiteaker, Partner, Propel Venture Partners | Jillian Williams, Investor, Anthemis Group | Troy Williams, Managing Director, University Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sanjay Zimmermann, Associate, White Star Capital and many more.


Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive a special discount of 10% off the existing “early bird” savings.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 


Register Today & Save Click here.   

(Use promo code “LPBI-VIP”)


In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 




Get Noticed > Get Funded > Grow Faster


A select group of more than 100 Top Innovators from the Life Sciences/Healthcare sector will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.


Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.


Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.


We look forward to seeing you there. 


Leaders in Pharmaceutical Business Intelligence (LPBI) Group


youngStartup Ventures


REAL TIME Press Coverage for 


 Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal,

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine,





Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series


2019 New England Venture Summit, December 3rd & 4th 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS



Wednesday, December 4th, 2019

8:00 am


8:50 am


9:00 am


Venture Capital thought leaders debate the challenges and opportunities facing Investors and Entrepreneurs

9:50 am


10:00 am


11:00 am


11:40 am


12:50 pm


1:00 pm


1:50 pm


3:00 pm


Ideas are all well and good, but in order to attract capital they will need to be packaged and presented in a way that will entice investors and of course a SOLID business model.  This panel will discuss the skills required to make a highly effective pitch that will attract potential financiers and the types of deals investors want.

3:00 pm


This session will discuss the trends in the financial markets and the future of venture capital investment in clean-tech.

3:00 pm


Ed-tech Investors will take center stage to grade the Ed-tech sector and share insights on the trends they’re seeing.

3:50 pm


4:30 pm


Entrepreneurs who don’t prepare well for term-sheet negotiations may find themselves locked into an uncomfortable relationship with their VC for years to come.  Whether you’re looking for a first round or follow-up funding, attend this panel to learn what you should know about negotiating term sheets.

4:30 pm


With a new flowering of startup innovation, many giants of industry have decided to enter or re-enter the world of VC. This session will explore the value-added investment approach of Corporate VCs and how it yields important dividends that are “beyond the bottom line,” both for the investor and for the startup.

5:20 pm


5:30 pm



Read Full Post »

15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA


The 15th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented by artificial intelligence, advanced data analytics, and digital health applications can empower both physicians and patients with information about how an expanded set of biological characteristics — including those found in the proteome and microbiome — may influence their health and their responses to increasingly impactful therapies.



at the Isabella Stewart Gardner Museum, 25 Evans Way, Boston, MA 02115




Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for 

In attendance generating in realtime event’s eProceeding and social media coverage by


Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston



(M) 617-775-0451,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile







Diagnosing, Different


8:00 a.m.
Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:55 a.m.
Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

9:00 a.m.
The Era of the ‘Living Drug:’ A Keynote Conversation With Dr. Carl June, Pioneer of CAR T-cell Therapy

During this opening keynote session, the University of Pennsylvania’s Dr. Carl June, the discoverer of the chimeric antigen receptor (CAR) T-cell therapies that are unlocking a new era of personalized cancer care, will join Immatics US Chief Medical Officer Dr. Stephen L. Eck for a wide-ranging conversation about the future of personalized medicine, touching on issues including but not limited to access and affordability, regulation and manufacturing, and T-cell therapies beyond cancer.
» Read More

MODERATOR | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US

Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania

9:45 a.m.
Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine

Emerging personalized medicine technologies may help facilitate earlier interventions that eliminate the need for expensive treatment of advanced diseases that have devastating consequences for patients. They can also help target treatments to only those patients who will benefit. But the success of these technologies depends on whether they can be integrated into a health system that has historically focused on treating diseases after symptoms have intensified, usually based on the assumption that every patient taking a given medication will respond to the treatment in a similar way.

During this session, Section 32 Managing Partner Michael J. Pellini, M.D., M.B.A., will moderate a discussion between industry representatives and a payer about the value proposition and outlook for disruptive technologies that are designed to support more informed disease prevention and treatment plans. The conversation will focus on how developments in areas including but not limited to artificial intelligence, data analytics, genomic sequencing, liquid biopsies, and proteomics may impact the prevention, diagnosis, and treatment of diseases including cancer, cardiovascular diseases, and diabetes.
» Read More

MODERATOR | Michael J. Pellini, M.D., Managing Partner, Section 32

Nancy Mendelsohn, M.D., Chief Medical Officer, Special Needs Initiative, UnitedHealth Group

Joshua Ofman, M.D., Chief of Corporate Strategy and External Affairs, Grail

Eric Schadt, Ph.D., CEO, Sema4

Roy Smythe, M.D., CEO, SomaLogic

10:30 a.m.
Networking Break
11:15 a.m.
Developing Diagnostics — Opportunities and Challenges in Personalized Medicine: A Two-Part Discussion

Diagnostic test developers are working to make personalized medicine possible by giving physicians tools that help them select the optimal treatment for every patient. Doing so requires that they navigate a complex business and policy landscape while being mindful of the day-to-day needs of payers and health care providers.

In this context, Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific, will take 10 minutes to introduce this two-part discussion titled “Developing Diagnostics — Opportunities and Challenges in Personalized Medicine.”

INTRODUCTION | Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

Discussion Part 1
Developing Diagnostics — From Concept to the Clinic: Perspectives on the Landscape for Developing and Integrating Personalized Medicine Diagnostics into Health Systems

To kick off the “Developing Diagnostics” discussion, Moffitt Cancer Center’s DeBartolo Family Personalized Medicine Institute Medical Director Howard McLeod, Pharm.D., will moderate a conversation among leaders from the clinical, diagnostics, IT, and pharmaceutical communities about the landscape for developing and integrating personalized medicine diagnostics into health systems.
» Read More

MODERATOR | Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center

Assaf Halevy, Founder, CEO, 2bPrecise

Kris Joshi, Ph.D., Executive Vice President, President, Network Solutions, Change Healthcare

Peter Maag, Ph.D., CEO, CareDx

Hakan Sakul, Ph.D., Vice President, Head of Diagnostics, Worldwide R & D and Medical, Pfizer

Kenna R. Mills Shaw, Ph.D., Executive Director, MD Anderson Institute for Personalized Cancer Therapy

Discussion Part 2
Developing Diagnostics — The Role of Research: A Closer Look at Efforts to Encourage the Clinical Adoption of Personalized Medicine Diagnostics by Studying the Clinical and Economic Utility of Genomic Sequencing

During the second portion of the “Developing Diagnostics” session, a health care provider, a health economist, an industry leader, and a payer representative will join moderator and Personalized Medicine Coalition Senior Vice President for Science Policy Daryl Pritchard, Ph.D., to examine the impact of emerging research on the clinical and economic utility of genomic sequencing for patients with diseases including but not limited to cancer and suspected rare diseases.

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

Roy J. Gandolfi, M.D., Medical Director, SelectHealth

Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare

Peter J. Neumann, Sc.D., Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center

Ammar Qadan, Vice President, Global Head of Market Access, Illumina

12:55 p.m.
Seated Luncheon
2:00 p.m.
Preparing Policies: A Keynote Address on the Policy Landscape for Personalized Medicine by Dr. Scott Gottlieb, Resident Fellow, American Enterprise Institute

During this keynote address, former U.S. Food and Drug Administration (FDA) commissioner Dr. Scott Gottlieb, who is now serving as Resident Fellow at the American Enterprise Institute, will share his thoughts on the evolving policy landscape for personalized medicine.
» Read More

SPEAKER Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute

2:45 p.m.
The 15th Annual Leadership in Personalized Medicine Award

After accepting the 15th Annual Leadership in Personalized Medicine Award, Genomic Health Chief Scientific Officer Dr. Steven Shak will share his vision for the future of the field with conference attendees.
» Read More

AWARDEE | Steven Shak, M.D., Chief Scientific Officer, Genomic Health

3:15 p.m.
Networking Break
4:00 p.m.
Wellness in the Workplace: Understanding the Opportunities and Challenges Associated With Employer-Sponsored Genetic Testing Programs for Healthy Patients

Reasoning that genetic testing may encourage healthy lifestyles by providing information about an employee’s relative risk of developing various diseases, employers seeking to improve patients’ lives and mitigate downstream health care costs have begun to sponsor genetic testing for healthy employees by partnering with various genetic testing companies, some of which sell the tests directly to consumers.

This session, moderated by Quest Diagnostics Chief Medical Officer Jay G. Wohlgemuth, M.D., who is responsible for overseeing health care benefits for Quest’s employees, will spotlight two employer-sponsored genetic testing partnerships and explore the relevant issues. The panel discussion will focus on the significance of information generated from genetic testing, the differences between various genetic testing business models, and the privacy risks associated with the collection of genetic data.

MODERATOR | Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Quest Diagnostics

Jane Cheshire Gilbert, C.P.A., Director, Retiree Health Care, Teachers’ Retirement System of Kentucky

Karen E. Knudsen, Ph.D., Executive Vice President, Oncology Services, Jefferson Health; Enterprise Director, Sidney Kimmel Cancer Center at Thomas Jefferson University

Othman Laraki, CEO, Color Genomics (invited)

Scott Megill, President, CEO, Coriell Life Sciences

5:00 p.m.
Overcoming Opioids: Considering the Potential of Personalized Medicine to Address the Opioid Crisis in the US

Emerging technologies present new opportunities to study the genetic, biological, and environmental factors that drive public health crises, with an eye toward developing personalized medicine health care strategies that can mitigate their devastating consequences.

To kick off this session, Dr. Avenel Joseph, Director of Policy and Oversight for the Office of Sen. Edward J. Markey, will define the larger context for the opioid crisis in Massachusetts and the rest of the country before Dr. Alissa M. Resch, Chief Scientific Officer, Coriell Institute for Medical Research, announces findings from Coriell’s ongoing effort to inform interventions that may help prevent opioid addiction by identifying with more precision which patients are most likely to develop dependency on this class of drugs.

INTRODUCTION | Avenel Joseph, Ph.D., Director of Policy and Oversight, Office of Sen. Edward J. Markey (invited)

SPEAKER | Alissa M. Resch, Ph.D., Chief Scientific Officer, Coriell Institute for Medical Research

5:30 p.m.
Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

6:15 p.m.
Welcome Reception at the Isabella Stewart Gardner Museum


Targeting Treatment

8:00 a.m.
Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:55 a.m.
Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US

9:00 a.m.
Going Global: Learning From Governmental Efforts to Advance Personalized Medicine Around the World

Global leaders are working to accelerate an era of personalized medicine around the world by encouraging innovation, modernizing policies, and reforming health systems to speed the clinical adoption of personalized medicine products and services.

During this panel discussion, four governmental representatives will share their visions for the future of personalized medicine and elaborate on their efforts to accelerate progress in the field.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS (European Infrastructure for Translational Medicine)

Asmaa Ali J. F. Althani, Ph.D., Dean, College of Health Sciences, Qatar University; Chair, Qatar Genome Program Committee; Board Vice Chairperson, Qatar Biobank

Noella Bigirimana, Strategic Advisor, Rwanda Biomedical Center, Ministry of Health, Government of Rwanda

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

Raquel Yotti, M.D., Ph.D., General Director, Instituto de Salud Carlos III (Spain)

10:00 a.m.
Innovation in the Era of Personalized Medicine: A Keynote Conversation With Dr. Paul Stoffels, Chief Scientific Officer, Johnson & Johnson

During this fireside chat with CNBC Reporter Meg Tirrell, Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will help frame the second half of the conference program by sharing the pharmaceutical industry’s perspective on the emerging issues in health care, touching on topics including costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson

10:30 a.m.
Networking Break
11:00 a.m.
Prospecting the Pipeline: Exploring the Implications of a Biopharmaceutical Pipeline Dominated by Personalized Treatments

As researchers develop an enhanced understanding of the molecular causes that underpin various diseases, many biopharmaceutical companies have begun to develop therapies that are targeted to patient subgroups and even personalized to individual patients. In oncology, for example, there are reportedly more than 900 personalized “immunotherapy” treatments being tested in the clinic, with more than 1,000 in preclinical development. The challenging scientific questions and systemic implications associated with these new therapies do not always fit neatly into existing regulatory, payment, and care delivery frameworks.

During this session, CNBC Reporter Meg Tirrell will moderate a panel discussion that explores the scientific, regulatory, reimbursement, and other systemic issues associated with future gene editing treatments, gene therapies, immunotherapies, and targeted therapies. The panelists, who include an industry representative, a government payer, a researcher, and an academic leader, will also consider a new approach to immunotherapy for cancer patients in which a unique product is developed for every patient treated.

MODERATOR | Meg Tirrell, Reporter, CNBC

George Poste, Ph.D., D.Sc., Director, Complex Adaptive Systems, Arizona State University

Tamara Syrek Jensen, J.D., Director, Coverage and Analysis Group, U.S. Centers for Medicare and Medicaid Services (invited)

Harpreet Singh, Ph.D., CEO, Immatics Biotechnologies GmbH

Alex Vadas, Ph.D., Managing Director, Partner, LEK Consulting

12:00 p.m.
Bag Lunch
1:00 p.m.
Harvard Business School Case Study: Dementia Discovery Fund

This interactive case study discussion will explore how and why a group of government agencies, nonprofit organizations, and pharmaceutical companies came together to support the Dementia Discovery Fund, focusing on whether a disease-specific venture that seeks to create meaningful new medicines in part by capitalizing on the evolving science underpinning personalized medicine can successfully balance social and business objectives.

MODERATOR | Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator

2:00 p.m.
Toward a Shared Value Proposition in Health Care: Pursuing Value-Based Solutions in Research, Regulation, Reimbursement, and Clinical Adoption

To advance the principles of personalized medicine, the field’s proponents will need to align representatives from multiple sectors of the health system on a shared value proposition that recognizes the importance of addressing the shortcomings of one-size-fits-all medicine.

During this session, M2Gen Executive Chairman William S. Dalton, Ph.D., M.D., will convene a commercial payer, an industry representative, a patient, and a value assessment framework developer to explore research, regulatory, clinical adoption, and especially reimbursement solutions that will, in the interest of patients, advance the principles of personalized medicine.

MODERATOR | William S. Dalton, Ph.D., M.D., Executive Chairman, M2Gen

Bonnie J. Addario, Co-Founder, Chair, GO2 Foundation for Lung Cancer

Sarah K. Emond, M.P.P., Executive Vice President, Chief Operating Officer, Institute for Clinical and Economic Review

Anne-Marie Martin, Ph.D., Senior Vice President, Global Head of Precision Medicine, Novartis Pharmaceuticals Corporation

Michael Sherman, M.D., Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care

3:00 p.m.
Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Read Full Post »

Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, 25 Edwin H. Land Boulevard, Cambridge, MA




Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for 

Confirmation Number: 8ZNCBYNGHCK

In attendance generating in realtime event’s eProceeding and social media coverage by


Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston



(M) 617-775-0451,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile





Join us this year as we explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic. Using a variety of case studies, our speakers will illustrate methods that successfully cut time to market and highlight how artificial intelligence and genomics are expediting target discovery and drug development. In an agenda that includes presentations, panel discussions, and short technology demonstrations, you will learn how the latest science and regulatory strategies are helping us get drugs to patients faster than ever.


Day One, September 23, 2019

  • Novel approaches to silence disease drivers
  • The role of AI in expediting drug discovery

Monday, September 23

8:30 – 9:00 a.m. Introduction and Welcome Remarks James C. Foster, Chairman of the Board, President, and Chief Executive Officer, Charles River
9:00 – 9:30 a.m. 2019 Award Winner: A Silicon Valley Approach to Understanding and Treating Disease Matt Wilsey, Chairman, President, and Co-Founder, Grace Science Foundation
9:30 – 10:15 a.m. Keynote Session Brian Hubbard, PhD, Chief Executive Officer, Dogma Therapeutics
10:15 – 10:30 a.m. Break
10:30 – 11:15 a.m. Novel Approaches to Silence Disease Drivers Systemic Delivery of Investigational RNAi Therapeutics: Safety Considerations and Clinical Outcomes Peter Smith, PhD, Senior Vice President, Early Development, Alnylam Pharmaceuticals
11:15 a.m. – 12:00 p.m. Novel Approaches to Silence Disease Drivers: Considerations for Viral Vector Manufacturing to Support Product Commercialization Richard Snyder, PhD, Chief Scientific Officer and Founder, Brammer Bio
12:00 – 1:00 p.m. Lunch
1:00 – 1:45 p.m. Accelerating Drug Discovery Through the Power of Microscopy Images Anne E. Carpenter, Ph.D., Institute Scientist, Sr. Director, Imaging Platform, Merkin Institute Fellow, Broad Institute of Harvard and MIT
1:45 – 2:30 p.m. The Role of AI in Expediting Drug Discovery Target Identification for Nonalcoholic Steatohepatitis Using Machine Learning: The Case for nference Venky Soundararajan, PhD, Founder and Chief Scientific Officer, nference/Qrativ
2:30 – 2:45 p.m. Break
2:45 – 3:30 p.m. Technobite Sessions with Emulate Bio and University of Pittsburgh Drug Discovery Institute
3:30 – 4:15 p.m. Artificial Intelligence Panel Discussion: Real World Applications from Discovery to Clinic Moderated by Carey Goldberg, WBUR
4:15 – 4:45 p.m. Jack’s Journey Jake and Elizabeth Burke, Cure NF with Jack
4:45 – 5:00 p.m. Closing Remarks
5:00 – 6:00 p.m. Networking Reception



Day Two – September 24, 2019

  • How genomics is expediting drug discovery
  • Accelerating therapies through the regulatory process

Tuesday, September 24

8:45 – 9:00 a.m. Opening Remarks and Recap James C. Foster, Chairman of the Board, President, and Chief Executive Officer, Charles River
9:00 – 9:30 a.m. 2018 Award Winner Update David Hysong, Patient Founder and Chief Executive Officer, Shepherd Therapeutics William Siders, CDO, Shepherd Therapeutics
9:30 – 10:15 a.m. Advances in Human Genetics and Therapeutic Modalities Enable Novel Therapies Eric Green, Vice President of Research and Development, Maze Therapeutics
10:15 – 11:00 a.m. How Genomics is Expediting Drug Discovery Manuel Rivas, Assistant Professor, Department of Biomedical Data Science, Stanford University
11:00 – 11:15 a.m. Break
11:15 a.m. – 12:00 p.m. Genomics Panel Discussion: Signposting Targets That Will Speed the Path to Market Moderated by Martin Mackay, Co-Founder, RallyBio
12:00 – 1:00 p.m. Lunch
1:00 – 1:45 p.m Truly Personalized Medicines for Ultra-rare Diseases: New Opportunities in Genomic Medicine Timothy Yu, Attending Physician, Division of Genetics and Genomics and Assistant Professor in Pediatrics, Boston Children’s Hospital
1:45 – 2:30 p.m. Application of Machine Learning Technology for the Assessment of Bulbar Symptoms in ALS Fernando Vieira, Chief Scientific Officer, ALS Therapy Development Institute
2:30 – 2:45 p.m. Break
2:45 – 3:30 p.m. Accelerating Rare Disease Therapies Through the Regulatory Process Martine Zimmermann, Senior Vice President and Head of Global Regulatory Affairs, Alexion Pharmaceuticals, Inc.
3:30 – 4:00 p.m. Wearing ALL the Hats: From Impossible to Possible Allyson Berent, Chief Operating Officer, GeneTx Biotherapeutics
4:00 – 4:15 p.m. Closing Remarks


peter smith.jpg
richard snyder.jpg
Anne_Carpenter photo (003).jpg
Carey Goldberg.PNG
burke family.jpg

September 24, 2019

david hysong.png
bill siders.png
eric green.jpg
timothy yu.jpg

Read Full Post »

eProceedings for BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA, Real Time Coverage by Stephen J. Williams, PhD @StephenJWillia2



Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2



Real Time Coverage @BIOConvention #BIO2019: Machine Learning and Artificial Intelligence: Realizing Precision Medicine One Patient at a Time, 6/5/2019, Philadelphia PA

Reporter: Stephen J Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Genome Editing and Regulatory Harmonization: Progress and Challenges, 6/5/2019. Philadelphia PA

Reporter: Stephen J Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Precision Medicine Beyond Oncology June 5, 2019, Philadelphia PA

Reporter: Stephen J Williams PhD @StephenJWillia2


Real Time @BIOConvention #BIO2019:#Bitcoin Your Data! From Trusted Pharma Silos to Trustless Community-Owned Blockchain-Based Precision Medicine Data Trials, 6/5/2019, Philadelphia PA

Reporter: Stephen J Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Keynote Address Jamie Dimon CEO @jpmorgan June 5, 2019, Philadelphia, PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Chat with @FDA Commissioner, & Challenges in Biotech & Gene Therapy June 4, 2019, Philadelphia, PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Falling in Love with Science: Championing Science for Everyone, Everywhere June 4 2019, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships, 6/4/2019, Philadelphia PA

Reporter: Stephen J Williams PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Understanding the Voices of Patients: Unique Perspectives on Healthcare; June 4, 2019, 11:00 AM, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: Keynote: Siddhartha Mukherjee, Oncologist and Pulitzer Author; June 4 2019, 9AM, Philadelphia PA

Reporter: Stephen J. Williams, PhD. @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019:  Issues of Risk and Reproduceability in Translational and Academic Collaboration; 2:30-4:00 June 3, 2019, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3, 2019, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: After Trump’s Drug Pricing Blueprint: What Happens Next? A View from Washington; June 3, 2019 1:00 PM, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, 2019, Philadelphia PA

Reporter: Stephen J. Williams PhD @StephenJWillia2

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: Machine Learning and Artificial Intelligence: Realizing Precision Medicine One Patient at a Time

Reporter: Stephen J Williams, PhD @StephenJWillia2

The impact of Machine Learning (ML) and Artificial Intelligence (AI) during the last decade has been tremendous. With the rise of infobesity, ML/AI is evolving to an essential capability to help mine the sheer volume of patient genomics, omics, sensor/wearables and real-world data, and unravel the knot of healthcare’s most complex questions.

Despite the advancements in technology, organizations struggle to prioritize and implement ML/AI to achieve the anticipated value, whilst managing the disruption that comes with it. In this session, panelists will discuss ML/AI implementation and adoption strategies that work. Panelists will draw upon their experiences as they share their success stories, discuss how to implement digital diagnostics, track disease progression and treatment, and increase commercial value and ROI compared against traditional approaches.

  • most of trials which are done are still in training AI/ML algorithms with training data sets.  The best results however have been about 80% accuracy in training sets.  Needs to improve
  • All data sets can be biased.  For example a professor was looking at heartrate using a IR detector on a wearable but it wound up that different types of skin would generate a different signal to the detector so training sets maybe population biases (you are getting data from one group)
  • clinical grade equipment actually haven’t been trained on a large set like commercial versions of wearables, Commercial grade is tested on a larger study population.  This can affect the AI/ML algorithms.
  • Regulations:  The regulatory bodies responsible is up to debate.  Whether FDA or FTC is responsible for AI/ML in healtcare and healthcare tech and IT is not fully decided yet.  We don’t have the guidances for these new technologies
  • some rules: never use your own encryption always use industry standards especially when getting personal data from wearables.  One hospital corrupted their system because their computer system was not up to date and could not protect against a virus transmitted by a wearable.
  • pharma companies understand they need to increase value of their products so very interested in how AI/ML can be used.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:





# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Older Posts »